🔎 Trials Near Me

Utama › Mielofibrosis › Alabama

Kajian klinikal Mielofibrosis di Alabama

7 kajian untuk Mielofibrosis sedang mencari peserta di lokasi di Alabama.

Bandar di Alabama

Teks kajian rasmi (Bahasa Inggeris)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • University of Alabama, Birmingham
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04176198

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • University of Alabama At Birmingham, Birmingham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT07441694

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

  • University of Alabama at Birmingham, Birmingham
Mengambil pesertaFasa 1
4 Weeks – 75 Years · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06047886

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • University of Alabama Birmingham, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 66 · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06859424

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Birmingham
  • Massive Bio SYNERGY-AI site, Mobile
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • UAB Hospital, Birmingham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2025 · NCT06479135

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

  • University of Alabama at Birmingham, Birmingham
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Feb 2023 · NCT05280509

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.